AI assistant
REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2012
Dec 12, 2012
29977_dirs_2012-12-12_30913120-373b-4452-89d4-4bb8c0ec8722.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2012-12-10
Reporting Person: Aberman Michael S (VP Strategy and Investor Relat)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2012-12-10 | Common Stock | M | 7500.0 | $30.63 | Acquired | 18000.0 | Direct |
| 2012-12-10 | Common Stock | F | 1257.0 | $182.68 | Disposed | 16743.0 | Direct |
| 2012-12-10 | Common Stock | F | 2875.0 | $182.68 | Disposed | 13868.0 | Direct |
| 2012-12-11 | Common Stock | S | 1268.0 | $184.85 | Disposed | 12600.0 | Direct |
| 2012-12-11 | Common Stock | S | 2100.0 | $185.18 | Disposed | 10500.0 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-12-10 | Non-Qualified Stock Option (right to buy) | $30.63 | M | 7500.0 | Disposed | 2020-12-14 | Common Stock (7500.0) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 287.0 | Indirect |
Footnotes
F1: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
F2: Represents volume-weighted average price of sales of 1,268 shares of Company stock on December 11, 2012 at prices ranging from $184.63 to $184.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2012 at each separate price.
F3: Represents volume-weighted average price of sales of 2,100 shares of Company stock on December 11, 2012 at prices ranging from $185.00 to $185.50. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on December 11, 2012 at each separate price.
F4: The stock option award vests in four equal annual installments, commencing one year after the date of grant.
F5: Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.